BEYOND BODY MASS INDEX: UNCOVERING "HIDDEN" CARDIOMETABOLIC RISK IN NORMAL-WEIGHT TYPE 2 DIABETES PATIENTS USING WHTR AND AIP TRAJECTORIES

Doctors routinely rely on Body Mass Index (BMI) to assess weight-related health, but it often misses hidden cardiovascular dangers in patients with type 2 diabetes (T2DM) who look lean or have a normal weight. This review examines how visceral fat accumulation and silent changes in lipid quality drive vascular damage in these non-obese individuals, and how we can catch these risks early. Analyzing recent data from high-impact cohort studies, clinical trials, and meta-analyses published between 2021 and 2026, we evaluate two practical, non-traditional tools: the waist-to-height ratio (WHtR) and the atherogenic index of plasma (AIP). The gathered evidence shows that WHtR is a highly reliable marker for hormonally active visceral fat, flagging elevated cardiovascular mortality risks even when a patient's BMI appears perfectly healthy. Meanwhile, AIP acts as a sensitive window into blood chemistry, detecting dangerous small, dense LDL particles—the driving force behind "residual" vascular risk that standard cholesterol tests often miss. When used together, WHtR and AIP track both the physical presence of belly fat and its toxic metabolic output, making it much easier to spot subclinical blood vessel damage before severe complications set in. Ultimately, moving away from a strict reliance on BMI toward a combined WHtR/AIP approach offers a simple, affordable, and non-invasive strategy. This dual-predictor model eliminates dangerous clinical blind spots, helping primary care physicians provide timely, life-saving cardiovascular prevention for normal-weight patients living with type 2 diabetes.

Hali tarjima qilinmagan